Literature DB >> 11416261

The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions.

R Becker1, D Jakob, E I Uhle, T Riegel, H Bertalanffy.   

Abstract

The effectiveness of intrathecal opioid therapy when applied to different pain mechanisms, in particular neuropathic and nociceptive pain conditions, was studied retrospectively in 43 patients suffering from cancer pain. On the basis of clinical and radiological data, the pain mechanisms were categorized as nociceptive (n = 23) and neuropathic (n = 20). The average duration of treatment of nociceptive pain was 5 months, of neuropathic pain only 2.5 months. The initial median reduction of pain with intrathecal opioid therapy was 77.8% for nociceptive and 61.1% for neuropathic pain. Long-term results with patients suffering nociceptive pain showed a continuing good median pain reduction of 66.7%. Patients suffering from neuropathic pain showed poor long-term results (11.1% median pain reduction). Neuropathic pain in the extremities reacted least to the application of intrathecal opioids. Optimal results were obtained for nociceptive pain in the trunk area of the body. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11416261     DOI: 10.1159/000048379

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  7 in total

1.  Malignant psoas syndrome associated with gynecological malignancy: Three case reports and a review of the literature.

Authors:  Shiro Takamatsu; Kosuke Murakami; Hisamitsu Takaya; Takako Tobiume; Hidekatsu Nakai; Ayako Suzuki; Masaki Mandai; Noriomi Matsumura
Journal:  Mol Clin Oncol       Date:  2018-05-21

2.  Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model.

Authors:  Atsushi Nakamura; Minoru Hasegawa; Kazuhisa Minami; Tomoe Kanbara; Takako Tomii; Atsushi Nishiyori; Minoru Narita; Tsutomu Suzuki; Akira Kato
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

3.  Palliation of bone cancer pain by antagonists of platelet-activating factor receptors.

Authors:  Katsuya Morita; Seiji Shiraishi; Naoyo Motoyama; Tomoya Kitayama; Takashi Kanematsu; Yasuhito Uezono; Toshihiro Dohi
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

4.  Enhanced GABAergic synaptic transmission at VLPAG neurons and potent modulation by oxycodone in a bone cancer pain model.

Authors:  Keiko Takasu; Koichi Ogawa; Atsushi Nakamura; Tomoe Kanbara; Hiroko Ono; Takako Tomii; Yasuhide Morioka; Minoru Hasegawa; Masahiro Shibasaki; Tomohisa Mori; Tsutomu Suzuki; Gaku Sakaguchi
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

Review 5.  Intrathecal Therapy for Cancer-Related Pain.

Authors:  Brian M Bruel; Allen W Burton
Journal:  Pain Med       Date:  2016-04-28       Impact factor: 3.750

6.  Continuous intrathecal morphine administration for cancer pain management using an intrathecal catheter connected to a subcutaneous injection port: a retrospective analysis of 22 terminal cancer patients in korean population.

Authors:  Jong Hae Kim; Jin Yong Jung; Min Soo Cho
Journal:  Korean J Pain       Date:  2013-01-04

7.  Current aproach to cancer pain management: Availability and implications of different treatment options.

Authors:  Hrachya Nersesyan; Konstantin V Slavin
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.